Docetaxel met carboplatine versus docetaxel, een gerandomiseerde fase 2 studie bij patiënten met hormoonongevoelig prostaatkanker na eerdere respons op docetaxel-bevattende chemotherapie: RECARDO STUDIE.
Recruiting
- Conditions
- Hormone refractory prostate cancer
- Registration Number
- NL-OMON27233
- Lead Sponsor
- VU Medisch Centrum
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 150
Inclusion Criteria
1. Histologically proven prostate adenocarcinoma;
2. Hormone refractory prostate cancer;
Exclusion Criteria
1. More than 1 line of chemotherapy;
2. No prior platinum allowed;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival
- Secondary Outcome Measures
Name Time Method 1. Safety and tolerability;<br /><br>2. Magnitude and duration of PSA response;<br /><br>3. Tumor response in measurable direase;<br /><br>4. Overall survival;<br /><br>5. Quality of life.